We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 75.00 | 73.00 | 77.00 | 75.00 | 75.00 | 75.00 | 22,023 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investment Advice | 149k | -7.14M | -0.1082 | -6.93 | 49.49M |
Hot Features
Premium
RNS Number:9140M
Celsis International PLC
31 May 2005
Celsis International PLC ("the company")
DIRECTORS DEALINGS
31 May 2005: In order to satisfy bids arising from institutional demand, Sir
Christopher Evans, a non-executive director of the company, agreed on 27 May
2005 to sell 3,000,000 ordinary shares in the Company at 36p per share. These
shares formed part of a holding issued to Sir Christopher Evans in 1993 when the
company was founded.
Following these transactions, Sir Christopher Evans has a total holding of
2,479,741 shares, representing approximately 2.22% of the issued share capital
of company.
Enquiries:
Celsis International plc Tel. 01638 600 151
Jay LeCoque, chief executive officer
Jenny Parsons, corporate communications
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSUARKRVVRVORR
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
